CANCERKINE project receives funding from the Ministry of Science and Innovation

The project named CANCERKINE and title ‘Preclinical development of monoclonal antibodies against IL13Ra2 for cancer therapy’ has been selected to receive funding from the Ministry of Science and Innovation. The aim of CANCERKINE is the preclinical development of the anti-IL13Ra2 monoclonal antibody 5.5.4 and their by-products in order to further advance this biological therapeutic product [...]

2023-05-05T10:41:59+00:0023 December 2022|Tags: , , |

PROALT selected by the European Innovation Council to pitch at the EIC Investor Day with CUF

PROALT has been selected by the European Innovation Council (EIC) to pitch its innovative therapeutic solutions in oncology to top European investors at the EIC Investor Day with CUF. The event took place in Lisbon (Portugal) on 29 and 30 November 2022, where the Company has presented in the ‘Biotech & Pharmaceuticals session’ its antibodies [...]

2022-12-02T12:49:45+00:0030 November 2022|Tags: , , , |

ProAlt at Swiss Biotech Day in Basel, Switzerland

September 07th, 2021 The Swiss Biotech Day is one of the leading biotechnology conferences in Europe coming back on stage on September 7, 2021 after the worldwide COVID-19 pandemic and will take place at Basel Congress Center. Today, PROALT will present to investors and pharma companies the recent advances with the therapeutic monoclonal antibody PA-0661 [...]

2021-09-14T13:17:13+00:007 September 2021|Tags: , |

ProAlt selected to participate in the EIC Corporate Day with Merck

September 6th, 2021 Protein Alternatives (ProAlt) was selected by the European Innovation Council Business Acceleration Services to present to Merck its therapeutic antibody PA-0661 in oncology. ProAlt will be one of the 16 selected companies from 10 different countries that will present innovative projects to Merck on September 30. Merck, the multinational Healthcare, Life Science [...]

2021-09-14T11:13:12+00:006 September 2021|Tags: , , , |

ProAlt’s MetasCure project selected in the R&D and innovation programme of Madrid Region

January 14th, 2021 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022. MetastCure project, with title “Preclinical evaluation of [...]

2021-05-04T11:08:46+00:0014 January 2021|Tags: , , , |

METASTCURE colon cancer therapeutic project receives the Seal of Excellence recognition from the EU H2020 Programme

November 25th, 2020 PROALT’s project proposal named ‘METASTCURE – Anti cadherin-RGD monoclonal antibody PA-0661 for the treatment of metastatic colorectal cancer’ has received the Seal of Excellence recognition from the Enhanced European Innovation Council (EIC) pilot in EU. The EIC Accelerator programme is part of the Enhanced European Innovation Council pilot and provides grant and blended [...]

2020-11-27T14:44:08+00:0025 November 2020|Tags: , , , , |
Go to Top